Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS6559184 B2
Publication typeGrant
Application numberUS 10/139,203
Publication dateMay 6, 2003
Filing dateMay 3, 2002
Priority dateJul 9, 1997
Fee statusPaid
Also published asCA2295595A1, EP1005336A1, EP1005336A4, US6414027, US20020128314, WO1999002147A1
Publication number10139203, 139203, US 6559184 B2, US 6559184B2, US-B2-6559184, US6559184 B2, US6559184B2
InventorsGary W. Neal
Original AssigneeAndrosolutions, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Methods and compositions for treating male erectile dysfunction
US 6559184 B2
Abstract
Administration of a pharmaceutical composition in the form of a suppository comprising:
(a) a prostaglandin vasodilator;
(b) 15-hydroxyprostaglandindehydrogenase inhibitor: and
(c) a base material that is solid at room temperature and releases components (a) and (b) when inserted in the urethra,
is effective for the treatment of male erectile dysfunction.
Images(3)
Previous page
Next page
Claims(16)
What is claimed as new and desired to be secured by Letters Patent of the United States is:
1. A method for treating male erectile dysfunction, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition, which comprises:
(a) a prostaglandin;
(b) 15-hydroxyprostaglandindehydrogenase inhibitor; and
(c) a base material that is solid at room temperature and releases components (a) and (b) when inserted in the urethra,
wherein said pharmaceutical composition is in the form of a suppository.
2. The method of claim 1, wherein component (c) melts or dissolves when inserted in the urethra to release components (a) and (b).
3. The method of claim 1, wherein component (c) does not melt or dissolve when inserted in the urethra to release components (a) and (b).
4. The method of claim 1, wherein said prostaglandin vasodilator is selected from the group consisting of prostaglandin E-1; prostaglandin E-2; prostaglandin F-2α; prostaglandin A-1; prostaglandin B-1; prostaglandin D-2; prostaglandin E-M; prostaglandin F-M; prostaglandin H-2; prostaglandin I-2; 19-hydroxy-prostaglandin A-1; 19-hydroxy-prostaglandin B-1; prostaglandin A-2; prostaglandin B-2; 19-hydroxy-prostaglandin A-2; 19-hydroxy-prostaglandin B-2; prostaglandin B-3; prostaglandin F-1α; 15-methyl-prostaglandin F-2α; 16,16-dimethyl-Δ2-prostaglandin E-1 methyl ester; 15-deoxy-16-hydroxy-16-methyl-prostaglandin E-1 methyl ester; 16,16-dimethyl-prostaglandin E-2; 11-deoxy-15-methyl-prostaglandin E-1; 16-methyl-18,18,19,19-tetrahydrocarbacyclin; (16RS)-15-deoxy-16-hydroxy-16-methyl-prostaglandin E-1 methyl ester; (+)-4,5-didehydro-16-phenoxy-α-tetranor-prostaglandin E-2 methyl ester; 11-deoxy-11a,16,16-trimethyl-prostaglandin E-2; (+)-11a,16a,b-dihydroxy-1,9-dioxo-1-(hydroxymethyl)-16-methyl-trans-prostene; 9-chloro-16,16-dimethyl-prostaglandin E-2; arboprostil; iloprost; and CL 115,347.
5. The method of claim 1, wherein said prostaglandin vasodilator is selected from the group consisting of prostaglandin E-1, prostaglandin E-2, prostaglandin F-2α, prostaglandin D-2, prostaglandin F-1α, and 15-methyl-prostaglandin F-2α.
6. The method of claim 1, wherein said prostaglandin vasodilator is prostaglandin E1.
7. The method of claim 1, wherein said prostaglandin vasodilator is prostaglandin E2.
8. The method of claim 1, wherein said 15-hydroxyprostaglandindehydrogenase inhibitor is selected from the group consisting of glycyrrhizic acid, licorice, DHEA, spironolactone, sofalcone, etodolac, indomethacin, sulindac, sulphasalazine, anologs of sulphasalazine, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, oleic acid, linoleic acid, and arachadonic acid.
9. The method of claim 6, wherein said pharmaceutical composition comprises 0.1 μg to 10 mg of said prostaglandin E1; and 25 to 100 units of said 15-hydroxyprostaglandindehydrogenase inhibitor.
10. The method of claim 6, wherein said pharmaceutical composition comprises 0.1 μg to 10 mg of said prostaglandin E1; and 0.1 μg to 20 mg of a 15-hydroxyprostaglandindehydrogenase inhibitor selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, oleic acid, linoleic acid, and arachadonic acid.
11. The method of claim 6, wherein said pharmaceutical composition comprises 0.1 μg to 10 mg of said prostaglandin E1; and 0.1 mg to 20 mg of a 15-hydroxyprostaglandindehydrogenase inhibitor selected from the group consisting of etodolac, indomethacin, and sulindac.
12. The method of claim 7, wherein said pharmaceutical composition comprises 0.1 μg to 10 mg of said prostaglandin E2; and 25 to 100 units of said 15-hydroxyprostaglandindehydrogenase inhibitor.
13. The method of claim 7, wherein said pharmaceutical composition comprises 0.1 μg to 10 mg of said prostaglandin E2; and 0.1 μg to 20 mg of a 15-hydroxyprostaglandindehydrogenase inhibitor selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, oleic acid, linoleic acid, and arachadonic acid.
14. The method of claim 7, wherein said pharmaceutical composition comprises 0.1 μg to 10 mg of said prostaglandin E2; and 0.1 mg to 20 mg of a 15-hydroxyprostaglandindehydrogenase inhibitor selected from the group consisting of etodolac, indomethacin, and sulindac.
15. The method of claim 1, wherein said pharmaceutical composition is administered transurethrally.
16. The method of claim 1, wherein said pharmaceutical composition is administered meatally.
Description

This application is a divisional of U.S. patent application Ser. No. 09/215,295, filed Dec. 18, 1998, now U.S. Pat. No. 6,414,027 which is a continuation-in-pad of U.S. patent application Ser. No. 08/890,445, filed Jul. 9, 1997, now U.S. Pat. No. 6,103,765, and which claims benefit of U.S. Provisional Application No. 60/068,294, filed Dec. 19, 1997, the contents of all of which are incorporated herein by reference in their entireties.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to methods of treating male erectile dysfunction. The present invention further relates to pharmaceutical compositions useful for treating male erectile dysfunction.

2. Discussion of the Background

Impotence, or lack of a man's ability to have sexual intercourse, is often the subject of jokes. However, millions of men suffer from this condition. Impotence is generally characterized by an inability to maintain a penile erection, and is often referred to as erectile dysfunction. Erectile dysfunction affects men, regardless of age, place of birth, or prior sexual experience.

In the context of the present invention, the term “erectile dysfunction” refers to certain disorders of the cavernous tissue of the penis and the associated fascia which produce impotence, the inability to attain a sexually functional erection. Impotence is estimated to affect about 10 million men in the United States alone. Impotence results from disruption of any of numerous physiological or psychological factors which cause the blood flow to and from the penis to remain in balance thereby preventing retention of sufficient blood to cause rigid dilation of the corpus cavernosa and spongiosa. In the context of the present invention, the term “impotence” is used in its broadest sense as the inability to attain a sexually functional erection when desired.

Treatments for impotence include psychosexual therapy, hormonal therapy, administration of vasodilators such as nitroglycerin and α-adrenergic blocking agents (hereafter “α-blockers”), vascular surgery, implanted penile prostheses, vacuum devices and external aids such as penile splints to support the penis or penile constricting rings to alter the flow of blood through the penis, (see Robert J. Krause, et al. N. Eng. J. Med., vol. 321, No 24, Dec. 14, 1989). Many patients treat their impotence by self injection of vasoactive drugs directly into the corpora cavernosa (see: Forward 1st Symposium International Sur L'Erection Pharmacologique, Nov. 17-19, 1989, Paris, p. 2; Virag, et al., Angiology, vol. 35, pp. 79-87, (1984); and U.S. Pat. Nos. 4,127,118, 4,766,889, and 4,857,059, which are incorporated herein by reference). The drugs most commonly used include α-blockers, such as phenoxybenzamine and phentolamine; smooth muscle relaxants such as papaverine; prostaglandins having a vasoactive function such as prostaglandin E1 and combinations of such drugs having different receptor effects to enhance therapy. Intracavernous injection doses of papaverine are typically in the range of about 7.5 to 160 mg, while doses of phentolamine are in the range of about 0.1 to 10 mg and doses of prostaglandin E1 are in the range of about 2.5 to 50 micrograms (see for example, Kurkle, et al., Urol. Clin. of America, vol. 15, No. 4, pp. 625-629 (1988) and N. Ishii et al., J. of Urol., vol. 141, pp. 323-325 (1989). Vasoactive intestinal peptides have also been reported as producing erection upon intracavernous injection at doses of 10-100 μg (see H. Handelsman, Diagnosis and Treatment of Impotence, U.S. Dept. of Health Services, Agency for Health Care Policy and Research, April 1990).

However, patients often find the injections of vasoactive drugs psychologically disturbing, painful, traumatic, or inconvenient as evidenced by a high discontinuance rate (see S. Althouf, et al., Journal of Sex and Marital Therapy, vol. 15, No. 2, pp. 121-129 (1989). In addition, adverse side effects including priapism, corporeal nodules and diffuse fibrosis, drug tolerance, bruising and hematomas, swelling and ulceration of the penile skin at the injection site have also been reported.

U.S. Pat. No. 4,801,587 and EPA 0357581 disclose the administration of vasodilators via the male urethra to produce erections. The transurethral administration of testosterone has also been reported (see S. M. Milco, Bulletins et Memoirs de la Societa Roumaine D'Endocrinologie, Vol. 5, pp. 434-437 (1989)). It has also been suggested that cocaine administered transurethrally could contribute to an erection (JAMA, vol. 259, No. 21, page 3176 (1988)). A nitroglycerin coated, erection inducing condom is disclosed in U.S. Pat. No. 4,829,991.

However, to date there is no completely effective treatment for male erectile dysfunction. Thus, there remains a need for a method of treating male erectile dysfunction. There also remains a need for compositions which are effective for treating male erectile dysfunction. In particular, there remains a need for methods and compositions for treating impotence which are characterized by a reduced tendency to cause pain, priapism, corporeal nodules, diffuse fibrosis, and scarring.

SUMMARY OF THE INVENTION

Accordingly, it is one object of the present invention to provide novel methods for treating male erectile dysfunction.

It is another object of the present invention to provide methods for treating male erectile dysfunction involving topical, meatal, and/or transurethral administration of a pharmaceutical composition.

It is another object of the present invention to provide methods for treating male erectile dysfunction which exhibit a reduced tendency to cause pain or a burning sensation.

It is another object of the present invention to provide methods for treating male erectile dysfunction which exhibit a reduced tendency to cause priapism.

It is another object of the present invention to provide methods for treating male erectile dysfunction which exhibit a reduced tendency to cause corporeal nodules.

It is another object of the present invention to provide methods for treating male erectile dysfunction which exhibit a reduced tendency to cause diffuse fibrosis.

It is another object of the present invention to provide methods for treating male erectile dysfunction which exhibit a reduced tendency to cause scarring of the corpora spongiosum and cavernosa.

It is another object of the present invention to provide novel pharmaceutical compositions which are useful for treating male erectile dysfunction.

It is another object of the present invention to provide pharmaceutical compositions for treating male erectile dysfunction which exhibit a reduced tendency to cause pain or a burning sensation.

It is another object of the present invention to provide pharmaceutical compositions for treating male erectile dysfunction which exhibit a reduced tendency to cause priapism.

It is another object of the present invention to provide pharmaceutical compositions for treating male erectile dysfunction which exhibit a reduced tendency to cause corporeal nodules.

It is another object of the present invention to provide pharmaceutical compositions for treating male erectile dysfunction which are effective when applied topically, meatally, and/or transurethrally.

It is another object of the present invention to provide pharmaceutical compositions for treating male erectile dysfunction which exhibit a reduced tendency to cause diffuse fibrosis.

It is another object of the present invention to provide pharmaceutical compositions for treating male erectile dysfunction which exhibit a reduced tendency to cause scarring of the corpora spongiosum and cavernosa.

These and other objects, which will become clear in the course of the following detailed description, have been achieved by the inventor's discovery that pharmaceutical compositions, which are in the form of a urethral suppository, and which comprise:

(a) a prostaglandin vasodilator;

(b) a 15-hydroxyprostaglandindehydrogenase inhibitor; and

(c) a base material that is solid at room temperature and releases components (a) and (b) when inserted in the urethra,

are particularly effective for the treatment of male erectile dysfunction even at low doses.

In a preferred embodiment, component (c) is a base material that is solid at room temperature but melts or dissolves when inserted in the urethra to release components (a) and (b).

BRIEF DESCRIPTION OF THE DRAWINGS

Various other objects, features and attendant advantages of the present invention will be more fully appreciated as the same becomes better understood from the following detailed description when considered in connection with the accompanying drawings in which like reference characters designate like or corresponding parts throughout the several views and wherein:

FIG. 1 is a cross-sectional view of the male urethra;

FIG. 2 shows the profile of one embodiment of the present urethral suppository;

FIG. 3 shows the profile of one embodiment of the present urethral suppository;

FIG. 4 shows the profile of one embodiment of the present urethral suppository;

FIG. 5 shows the profile of one embodiment of the present urethral suppository;

FIG. 6 shows the profile of one embodiment of the present urethral suppository;

FIG. 7 shows a cross-sectional view of one embodiment of the present urethral; suppository;

FIG. 8 shows a cross-sectional view of one embodiment of the present urethral; suppository;

FIG. 9 shows a cross-sectional view of one embodiment of the present urethral suppository; and

FIG. 10 shows a cross-sectional view of one embodiment of the present urethral suppository.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Thus, in a first embodiment, the present invention provides novel pharmaceutical compositions which are useful for treating male erectile dysfunction. The present pharmaceutical compositions are characterized as being in the form of a urethral suppository and comprising:

(a) a prostaglandin vasodilator;

(b) a 15-hydroxyprostaglandindehydrogenase inhibitor; and

(c) a base material that is solid at room temperature and releases components (a) and (b) when inserted in the urethra.

Examples of suitable prostaglandins include, but are not limited to, PGE-1; PGE-2; PGF-2α; PGA-1; PGB-1; PGD-2; PGE-M; PGF-M; PGH-2; PGI-2; 19-hydroxy-PGA-1; 19-hydroxy-PGB-1; PGA-2; PGB-2; 19-hydroxy-PGA-2; 19-hydroxy-PGB-2; PGB-3; PGF-1α; 15-methyl-PGF-2α; 16,16-dimethyl-Δ2-PGE-1 methyl ester; 15-deoxy-16-hydroxy-16-methyl-PGE-1 methyl ester; 16,16-dimethyl-PGE-2; 11-deoxy-15-methyl-PGE-1; 16-methyl-18,18,19,19-tetrahydrocarbacyclin; (16RS)-15-deoxy-16-hydroxy-16-methyl-PGE-1 methyl ester; (+)-4,5-didehydro-16-phenoxy-α-tetranor-PGE-2 methyl ester; 11-deoxy-11a,16,16-trimethyl-PGE-2; (+)-11a,16a,b-dihydroxy-1,9-dioxo-1-(hydroxymethyl)-16-methyl-trans-prostene; 9-chloro-16,16-dimethyl-PGE-2; arboprostil; iloprost; CL 15.347: and semisynthetic or synthetic derivatives of these natural prostaglandins, or any derivative or any prostaglandin analog capable of acting as a vasodilator or neuromodulator. Cyclodextrin complexes are also included as they may enhance the activity of the solution and stabilize the prostaglandin. Racemic, optically enriched or purified stereoisomers of any of these compounds are also included. Physiologically acceptable salts are also included. Preferably, the prostaglandin is PGE-1, PGE-2, PGF-2α, PGD-2, PGF-1α, 15-methyl-PGF-2α, and CL 115,347. Most preferably, the prostaglandin is PGE-2 or PGE-1.

PGE-1, prostaglandin E1, is also known as alprostadil or PGE1. The formal chemical name of PGE-1 is 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid, and the structure of PGE-1 is

Prostaglandin E1 may be isolated from sheep seminal vesicle tissue as described in Bergstrom et al., Acta. Chem. Scand., vol. 16, p. 501 (1962) and J. Biol. Chem., vol. 238, p. 3555 (1963). The synthesis of prostaglandin E1 may be carried out as described in Corey et al., J. Am. Chem. Soc., vol. 91, p. 535 (1969); Corey et al., J. Am. Chem. Soc., vol. 92, p. 2586 (1970); Sih et al. J. Am. Chem. Soc., vol. 94, p. 3643 (1972); Sih et al., J. Am. Chem. Soc., vol. 95, p. 1676 (1973); Schaaf et al., J. Org. Chem., vol. 37, p. 2921 (1974), and Slates et al., Tetrahedron, vol. 30. p. 819 (1974).

PGE-2, prostaglandin E2 is also known as dinoprostone or PGE2. The formal chemical name of PGE-2 is 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoic acid, and the structure of PGE-2 is:

Prostaglandin E2 may be isolated from sheep seminal vesicle tissue as described in Bergstrom et al., Acta. Chem. Scand., vol. 16, p. 501 (1962). Prostaglandin E2 may be synthesized as described in Corey et al., J. Am. Chem. Soc., vol 92, p. 397 (1970); Corey et al., J. Am. Chem. Soc., vol. 92, p. 2586 (1970); and Heather et al., Tetrahedron Letters, p. 2313 (1973).

Both prostaglandin E1 and E2 are commercially available from Sigma Chemical Company of St. Louis. Mo. PGE-2 is also commercially available as a Prostin E-2 suppository and as Prepidil Gel from Pharmacia & UpJohn Company, Kalamazoo. Mich., and as Cervidil from Forrest Pharmaceuticals, Inc., St. Louis. Mo.

PGF-2α, prostaglandin F, is also known as dinoprost or PGF. The formal chemical name is 7-[3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid. PGF-2α may be prepared as described in U.S. Pat. No. 3,657,327, which is incorporated herein by reference.

15-Deoxy-16-hydroxy-16-methyl-PGE-1 methyl ester is also known as misoprostol and has the formal chemical name of (±)-methyl-(1R,2R.3R)-3-hydroxy-2-[(E)-(4RS)-4-hydroxy-4-methyl-1-octenyl]-5-oxocyclopentaneheptanoate. 15-Deoxy-16-hydroxy-16-methyl-PGE-1 methyl ester may be prepared as described in U.S. Pat. No. 3,965,143, which is incorporated herein by reference.

Enprostil has the formal chemical name of [1α,2β(1E.3R),3α]-7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-4,5-heptadienoic acid methyl ester. Enprostil may be prepared as described in U.S. Pat. No. 4,178,457. which is incorporated herein by reference.

PGI-2 is also known as prostacyclin, epoprostenol, prostaglandin I2, prostaglandin X, PGI2, and PGX. Prostacyclin may be prepared as described in U.S. Pat. No. 4,539,333, which is incorporated herein by reference.

The remaining prostaglandins are described in Alex Gringanz, Introduction to Medicinal Chemistry, Wiley-VCH, Inc., New York, pp. 158-159 and 641-642, 1997, which is incorporated herein by reference.

Cyclodextrin complexes of the prostaglandin may be used in order to increase the stability and efficacy. Cyclodextrin complexes may be prepared by adding the proper stoichiometric ratio of the prostaglandin to α,β, or γ cyclodextrin in an aqueous solvent and then either using as is or lyophilizing to provide a solid clathrate for mixing. These complexes are described in Yamamura et al, J. Chromatogr., vol. 331, pp. 383-388 (1985); Hirayama et al, Chem. Pharm. Bull., vol. 32 pp. 4237-4240 (1984); Uekama et al, J. Pharm. Sci., vol. 73, pp. 382-384 (1984); and Yamamura et al, J. Chromatogr., vol. 303, pp. 165-172 (1984), which are incorporated herein by reference.

Typically, the present composition will contain prostaglandin E, or prostaglandin E2 in an amount of 0.1 μg to 10 mg, preferably 10 to 1000 μg (for transurethral administration), preferably 25 to 2500, μg (for meatal administration), per unit dosage.

By the term “15-hydroxyprostaglandindehydrogenase inhibitor” it is meant any compound which exhibits a significant and selective inhibition of prostaglandin degrading enzyme, or 15-hydroxyprostaglandindehydrogenase (PGDH). Two forms of 15-hydroxyprostaglandindehydrogenase (PGDH) are known: Type 1. which is NAD+ dependent, and Type II, which is NADP+ dependent. Type I operates at a Km one order of magnitude lower than Type II and is thus more significant physiologically. Type I PGDH is described in Mak et al, Biochimica et Biophysics Acta, vol. 1035, pp. 190-196 (1990); Ensor et al, J. Lipid Mediators Cell Signalling, vol. 12. pp. 313-319 (1995); and Berry et al, Biochemical Pharmacology. vol. 32, no. 19, pp. 2863-2871 (1983), which are incorporated herein by reference. Partially purified bovine lung Type I PGDH is commercially available from BDH, Limited (Poole, UK). Berry et al., Tai et al., Muramatsu et al., and Mak et al. describe assays for determining enzymatic activity of Type I PGDH as well as methods for determining the degree of inhibition of this enzyme.

Type II PGDH is described in Chang, et al. Biochem. Biophys. Res. Commun., vol. 99, pp. 745-751 (1981); Jarabak, et al. Prostaglandins, vol. 18, pp. 241-246 (1979), and Lin, et al, Biochem. Biophys. Res. Commun., vol. 81, pp. 1227-1234 (1978), all of which are incorporated herein by reference.

Examples of suitable 15-hydroxyprostaglandindehydrogenase inhibitors include but are not limited to glycyrrhizic acid, licorice, glycyrrhetinic acid, various glycosides of glycrrhetinic acid, carboxenolone, DHEA, spironolactone, sofalcone, indomethacin, sulindac, etodolac, oleic acid, palmitic acid, and sulphasalazine and analogues thereof. Antibodies which bind to and inhibit Type I PGDH may also be used.

Glycyrrhizic acid is also known as glycyrrhizin, glycyrrhizinic acid, and glycyrrhetinic acid glycoside. The formal chemical name is 20β-carboxy-11-oxo-30-norolean-12-en-3β-yl-2-O-β-D-glucopyranuronosyl-α-D-glucopyranosiduronic acid, and the structure is:

Glycyrrhizic acid is commercially available from Sigma Chemical Company of St. Louis, Mo.

Glycyrrhetinic acid is unglycosylated glycyrrhizic acid, and its structure is:

Glycyrrhetinic acid may be obtained from licorice extract.

Carbenoxolone is also known as 3β-hydroxy-11-oxo-20β-olean-12-en-29-oic acid hydrogen butanedioate and has the following structure:

Carbenoxolone may be synthesized as described in U.S. Pat. No. 3,070,623, which is incorporated herein by reference.

Licorice is also known as sweet root liquorice and glycyrrhiza and is described in the Merck Index, 10th edition, citation 4368 as “glycyrrhiza, Licorice, liquorice; sweet root. Dried rhizome and root of Glycyrrhiza glabra L., var. typica Regel & Herder (Spanish licorice), or of G. Glabra L., var. glandulifera (Waldst. & Kit.) Regel & Herder (Russian licorice), or of other varieties of G. g yielding a yellow and sweet wood, Leguminosaw. Habt, Southern Europe to Central Asia. Constit, 6-14% glycyrrhizin (the glucoside of glycyrrhetic acid), asparagine, sugars, resin.”

Licorice is a crude preparation prepared from dried rhizomes or roots and as such contains large numbers of compounds many of which are not identified. A simple aqueous extract of a commercially available dried licorice root preparation may be prepared as follows. Two grams of this dried licorice root was mixed with 10 mls of distilled water, stirred until thoroughly mixed at room temperature and filtered to remove particulate matter. This simple aqueous extract of licorice is effective in inhibiting PGDH and may be used as is in the present invention.

Spironolactone is also known as Aldactone A or Verospiron. The formal chemical name of spironolactone is 17-hydroxy-7-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic and γ-lactone, 7-acetate, and the structure is:

Spironolactone is commercially available from Sigma Chemical Company of St. Louis, Mo.

Sofalcone is formally known as [5-[(3-methyl-2-butenyl)oxy]-2-[3-[4[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]acetic acid and has the formula:

Sofalcone may be prepared as described in U.S. Pat. No. 4,085,135, which is incorporated herein by reference.

DHEA is formally known as 3-hydroxyandrost-5-en-17-one or dehydroepiandrosterone or prasterone. The structure of DHEA is:

DHEA may be prepared as described in H. Hosoda et al, J. Org. Chem., vol. 38, p. 4209 (1973), which is incorporated herein by reference.

Sulfasalazine is also known as 2-hydroxy-5[[4-[(2-pyridinylamino)sulfonyl]phneyl]azo]benzoic acid and has the structure:

A number of sulfasalazine analogs have been shown to be inhibitors of PGDH by Berry et al, Biochemical Pharmacology, vol. 32, pp. 2863-2871 (1983). Examples of sulfasalazine analogs which may be used as the PGDH inhibitor in the present compositions include:

Etodolac is also known as 1.8-diethyl-1.3.4,9-tetrahydropyrano-[3.4-b]indole-1-acetic acid. Etodolac may be prepared as described U.S. Pat. No. 3,843,681. which is incorporated herein by reference.

Indomethacin is also known as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. Indomethacin may be prepared as described in U.S. Pat. No. 3,161,654, which is incorporated herein by reference.

Sulindac is also known as 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid. Sulindac may be prepared as described in U.S. Pat. Nos. 3,654,349 and 3,647,858, which are incorporated herein by reference.

Other types of 15-hydroxyprostaglandindehydrogenase inhibitors include aliphatic and aromatic carboxylic acids. Suitable carboxylic acids particularly include any straight chain or branched, saturated, monounsaturated, or polyunsaturated aliphatic C8-C31 carboxylic acid. Particularly preferred for use as component (b) in the present suppositories are free fatty acids including, but not limited to, palmitic acid, oleic acid, stearic acid, capric acid, lauric acid, myristic acid, linoleic acid, arachidic acid and arachadonic acid, all of which are commercially available from Sigma Chemical Co., St. Louis, Mo.

The 15-hydroxyprostaglandindehydrogenase inhibitor will typically be present in an amount of 25 to 100, preferably 50 to 100, pig penile units of PGDH inhibition activity, per unit dosage. The amount of inhibitor which corresponds to a unit of pig penile PGDH inhibition activity is determined using either the spectrophotometric or radio-chemical assay described in the Examples. For inhibitors which exhibit a significant absorption at 340 nm, it is preferred to use the radio-chemical assay.

When the 15-hydroxyprostaglandindehydrogenase inhibitor is a fatty acid, such as palmitic acid, oleic acid, stearic acid, capric acid, lauric acid, myristic acid, linoleic acid, arachidic acid and arachadonic acid, the fatty acid will suitably be present in the suppository in an amount of from about 0.1 μg to about 20 mg, preferably from about 100 μg to about 10 mg.

When the 15-hydroxyprostaglandindehydrogenase inhibitor is etodolac, sulindac, or indomethacin, the suppository will suitably contain the-15-hydroxyprostaglandindehydrogenase inhibitor in an amount of 01 Mg to 20 mg, preferably 0.5 mg to 10 mg, per unit dosage of prostaglandin.

Component (c), the base or carrier material, may be composed of any material or mixture of materials that is compatible with component (a), the prostaglandin vasodilator, and component (b), the 15-hydroxyprostaglandindehydrogenase inhibitor, and which releases components (a) and (b) upon insertion into the meatus or urethra. Examples of materials suitable for use as component (c) which releases components (a) and (b) upon insertion of the suppository into the urethra include materials such as hydrogels which contain or are saturated with components (a) and (b).

Examples of suitable gels include triacetin, hydroxycellulose, gels composed of water, propylene glycol, hydroxypropyl methylcellulose and any other gels which are compatible with the prostaglandin. A particularly preferred gel is lecithin organogel prepared according to H. Willimann et al, “Lecithin organolgel as matrix for transdermal transport of drugs,” J. Pharm. Sci., vol. 81(9), pp. 871-874 (1992), which is incorporated herein by reference. This particular preparation exhibits a dramatically enhanced potency.

One may also use a gel in which one or more of the prostaglandins or co-agents is released in a controlled-released manner (i.e., released over time) to prolong the effect of the composition. For example, components (a) and (b) can be formulated into a cross-linked polyethylene oxide/urethane polymer which is well tolerated by living tissues and releases components (a) and (b) in a controlled release manner. Controlled release compositions are disclosed in D. H. Lewis, Controlled Release of Pesticides and Pharmaceuticals, Plenum Press, New York, 1981; and A. F. Kydonieus, Controlled Release Technologies: Methods, Theory, and Applications, CRC Press, Boca Raton, 1980, which are incorporated herein by reference.

In a preferred embodiment, component (c) is a material or mixture of materials which is compatible with component (a), the prostaglandin vasodilator, and component (b), the 15-hydroxyprostaglandindehydrogenase inhibitor, and which results in the final composition having a melting point ranging from about 70° to about 100° F., preferably from about 70° to about 90° F.

Specific examples of suitable materials for use as component (c) include but are not limited to fatty acid esters, such as ethyl stearate, methyl stearate, isopropyl stearate, butyl stearate, and cetyl lactate; fatty acid ethers, such as laureth 9; cholesterol esters, such as cholesteryl oleate and cholesteryl palmitate; cholesterol ethers; fatty acid diglycerides; fatty acid triglycerides; fatty acids; phospholipids; glycolipids: and sphingolipids. Ethyl stearate is a particularly preferred compound for use as component (c).

Other materials suitable for use as component (c) include polyethylene glycol (PEG). The PEG is chosen so that the suppository is a solid or semisolid at room temperature but melts/dissolves rapidly in the urethra. Good results have been achieved using PEG with an average molecular weight of about 1450.

The present suppositories may further comprise one or more co-agents. Examples of suitable co-agents include:

1. ACE inhibitors, including but not limited to captopril, enalapril, enalaprilat, quinapril, lisinopril, and ramipril, may enhance the efficacy of the present method and decrease long term complications, such as inflammatory and fibrotic responses;

2. Nitro vasodilators, including but not limited to nitroglycerin, isosorbide dinitrate, amyl nitrate, isosorbide mononitrate, erythrityl tetranitrate, and sodium nitroprusside, may enhance the efficacy of the present method;

3. Alpha blockers, including but not limited to prazosin, phentolamine, phenoxybenzamine, dibenzaamine, doxazosin, terazosin, trimazosin, tolazoline, corynthanine, rauwolscine, and piperoxan, are especially desirable for increasing the efficacy and prolonging the action of the present method;

4. Other adrenoreceptor agents, including but not limited to yohimbine, labetalol, carvedilol, and bucindolol, may also enhance the activity and prolong the action of the present method;

5. Phosphodiesterase (PDE) inhibitors, including but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast. dipyridamole, and sildenafil, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

6. Muscarinic agents such as pilocarpine, edrophonium, and bethanacol;

7. Dopaminergic agonists such as apomorphine and bromocriptine;

8. Ergot alkaloids such as ergotamine and ergotamine analogs, including acetergamine, bravergoline, bromerguride, clanegollone, ergonovine, ergotamine tartrate, and pergolide;

9. Opiate antagonists such as naloxone, naltrexone, nalmefene, nalorphine, methyl naltrexone, CTOP, diprenorphine, β-funaltrexamine, naloxonazine, nor-binaltorphimine, natrindole, BNTX, and other analogs, which exhibit opioid antagonistic properties;

10. Polypeptide neurotransmitters such as VIP, calcitonin, calcitonin gene related product, VIP analogs, and cholecystokinin and all its analogs such as CCK8; and

11. Mast cell stabilizers such as chromolyn, nedochromolyn, zileuton, piripost, MK-886. MK-0591, ICI-D2318, docebenone, and leukotriene receptor antagonists.

Particularly desirable compositions include alpha-blockers and/or PDE inhibitors. Any combinations of the single above-listed compounds or multiple combinations of different compounds or different groups may also be used. In some instances, it may be advantageous to pretreat with one or more of the co-agents. For example, pretreatment with a PGDH inhibitor followed by treatment with PGE will enhance the efficacy of the present method.

The present urethral suppositories will typically be oblong in shape with a length to width aspect ratio of from about 1:1 to about 75:1, preferably from about 5:1 to about 20:1. The length of the suppository may vary from about 1 mm to about 100 mm. preferably from about 2 mm to about 75 mm. The length of the suppository may be tailored to direct the dosage of the prostaglandin to either the urethral meatus or the penile urethra. When administration to the urethral meatus is desired, the length of the suppository is preferably from about 2 mm to about 60 mm, more preferably from about 5 mm to about 50 mm, and most preferably from about 10 mm to about 40 mm. In contrast, when administration to the penile urethra is desired, the length of the suppository is preferably from about 50 mm to about 100 mm, more preferably from about 60 mm to about 100 mm, and most preferably from about 60 mm to about 80 mm.

FIGS. 2-6 show the profile or side view of some embodiments of the present suppository, while FIGS. 7-10 show the cross-sectional view of some embodiments of the present suppository. FIG. 2 shows the side view of a suppository with a straight shaft 1 and a rounded tip 2. FIG. 3 shows the side view of a suppository with a straight shaft 1 and a pointed tip 2. FIG. 4 shows the side view of a suppository with a straight shaft 1, a rounded tip 2, and flat base or stop 3 attached to the end of the shaft 1 distal to the tip 2. FIG. 5 shows the side view of a suppository with a straight shaft 1, a pointed tip 2, and flared base or stop 3 attached to the end of the shaft 1 distal to the tip 2. FIG. 6 shows the side view of a suppository which is tapered along the entire length of the shaft 1 and has a pointed tip 2.

The present suppository is not limited to any particular cross-sectional shape. As shown in FIGS. 7-10, the present suppositories may be either circular, elliptical oblong, or football-shaped in cross-section. Circular and elliptical cross-sectional shapes are preferred. FIG. 7 shows the cross-sectional view of a suppository which does not have a base or stop 3 and in which the shaft 1 is substantially circular in cross-section. FIG. 8 shows the cross-sectional view of a suppository which does not have a base or stop 3 and in which the shaft 1 is substantially oblong in cross-section. FIG. 9 shows the cross-sectional view of a suppository which has a base or stop 3 which is substantially circular and in which the shaft I is substantially circular in cross-section. FIG. 10 shows the cross-sectional view of a suppository which has a base or stop 3 which is substantially circular and in which the shaft 1 is substantially oblong in cross-section.

In one preferred embodiment, the suppository has a round or pointed tip to facilitate entry into the urethra (see FIGS. 2-5). Alternatively, the suppository may be tapered along all of or at least a substantial part of its length (see FIG. 6). The base of the suppository may be distended or flared to provide a built-in stop, so that the depth of the insertion may be determined by the length from the tip of the suppository to the beginning of the flare (see FIGS. 4 and 5). Alternatively, the base of the suppository may be attached to a piece of foil, plastic, or paper or attached to the inside of the tip of a condom in order to set the depth of insertion.

The present suppositories will typically have a cross-section having a maximum dimension of from about 0.1 mm to about 25 mm, preferably from about 1 mm to about 10 mm, particularly from about 2 mm to about 6 mm, along the portion of the suppository intended to be inserted into the urethra. Although there is in principal no lower limit on the minimum cross-sectional dimension along the portion of the suppository intended to be inserted into the urethra, practically speaking, the suppository should be thick enough to retain sufficient structural integrity to permit insertion of the suppository into the urethra without breaking or significantly bending the suppository.

As noted above, the present suppository may have a shape in which the base of the suppository is distended or flared. The distended or flared portion of the suppository will typically have a minimum dimension of at least about 5 mm, preferably at least about 10 mm. Although there is in principal no upper limit on the maximum cross-sectional dimension of the distended or flared portion of the suppository, practically speaking, it is not necessary to make the distended or flared portion any larger than what is required to prevent insertion of the suppository into the urethra beyond the point at which the distended or flared portion begins.

Typically, the suppository will contain sufficient amounts of (a) and (b) such that administration of a single suppository is sufficient to provide the desired result. Thus, a suppository would typically contain: (a) 0.1 μg to 10 mg, preferably 10 μg to 1000 μg (for transurethral administration), preferably 25 μg to 2500 μg (for meatal administration), of prostaglandin E1, or 0.1 μg to 10 mg, preferably 10 μg to 1000 μg (for transurethral administration), preferably 25 μg to 2500 μg (for meatal administration), of prostaglandin E2; and (b) 25 to 100 pig penile units, preferably 50 to 100 pig penile units, of the 15-hydroxyprostaglandindehydrogenase inhibitor.

In a particularly preferred embodiment, the present suppository contains 0.02 to 2 mg of oleic acid per each mg of prostaglandin E2 (i.e., a 0.02:1 to 2:1 weight ratio of oleic acid:prostaglandin E2). In another particularly preferred embodiment, the present suppository contains prostaglandin E2 and palmitic acid in a prostaglandin E2:palmitic acid weight ratio of 0.09:1 to 9:1.

In a preferred embodiment, the present suppositories are characterized as having a pH of 3 to 7, preferably 4 to 6. Such suppositories may be prepared by simply adding a sufficient amount of a pharmaceutically acceptable acid or base, e.g., HCl or NaOH to adjust the pH to the desired value. In a particularly preferred embodiment, one may add to each unit dose the residual powder from 0.5 ml of a 0.01 Molar aqueous solution of a pharmaceutically acceptable citrate salt, e.g., sodium citrate, which has the desired pH. For example, 0.5 ml of 0.01 Molar sodium citrate at pH 4.5 is lyophilized, and the powdered residue is added to a unit dose of prostaglandin E2 in polyethylene glycol (PEG) MW 1450. Upon insertion of this dose into the urethra, the lyophilized citrate will dissolve and buffer the pH of the urethra to about pH 4.5 and thereby enhance the activity of the prostaglandin E2 as the PEG pellet dissolves.

In a second embodiment, the present invention provides a method for treating male erectile dysfunction, by administering the present suppository to a patient in need thereof. The present method may be carried out by either transurethral administration or meatal administration of the present suppository.

As shown in FIG. 1, the male penile urethra consists of three segments: the bulbar urethra, the pendulous urethra, and the navicular fossa. The term “transurethral administration” as used herein refers to the administration of agents to the bulbar and pendulous urethra which are covered by pseudostratified or stratified columnar epithelium. The term “meatal administration” as used herein refers to the administration of agents to the urethra of the navicular fossa and/or to the penile meatus (as shown in FIG. 1) that are covered by stratified squamous epithelium. Meatal administration is thus essentially the same as topical administration with respect to the difficulty of administering an effective transdermal dose. Conventionally, a meatal dose of a vasoactive prostaglandin would typically be expected to be 10 to 20 (or more) times greater than a transurethral dose due to the difficulty of traversing the denser epithelium. However, the present suppositories exhibit the improvement of making meatal administration feasible and effective even when using the same dosage as effective in transurethral administration.

Meatal administration is preferred over transurethral administration for a number of reasons. Meatal administration is generally easier to carry out than transurethral administration and may be the only possible means of administration in patients with narrowing or scarring of the urethra. The depth of insertion of the suppository in meatal administration is, as measured from the external opening of the penis, between 2 mm and 60 mm. In contrast, the depth of insertion of the suppository in transurthral administration is, as measured from the external opening of the penis, greater than 50 mm. Meatal or transurethral administration may be easily effected by selection of a suppository with a shaft of the appropriate length and a distended or flared base and insertion of the suppositories to the depth of the distended or flared base.

Typically, the suppository is inserted into the urethra 1 to 50 minutes, preferably 10 to 20 minutes, prior to the time of commencing sexual intercourse. Meatal administration may result in a slower onset of the effect of the active agent and, thus, may preferably be carried out earlier than transurethral administration.

Those suppositories in which component (c) dissolves or melts in the urethra are simply inserted into the urethra. Those suppositories in which component (c) releases components (a) and (b) in the urethra but does not itself dissolve or melt in the urethra are preferably inserted into the urethra to a depth which leaves a portion of the suppository protruding from the urethra, left in the urethra until the desired affect is achieved, and then removed from the urethra by means of the protruding portion.

Of course, it is also to be understood that the prostaglandin E1 or prostaglandin E2 need not be administered simultaneously with the 15-hydroxyprostaglandindehydrogenase inhibitor. Rather, the 15-hydroxyprostaglandindehydrogenase inhibitor may be preadministered in a first suppository followed by treatment with the prostaglandin in a second suppository. Pre-treatment or simultaneous treatment with a 15-hydroxyprostaglandindehydrogenase inhibitor decreases the burning sensation associated with the administration of the prostaglandin. In addition, the blocking of the PGDH enhances tremendously the absorption and effectiveness of the prostaglandin leading to a remarkably lower dose requirement.

Since PGDH degrades most pharmacologically active prostaglandins, not just PGE1 and PGE2, the inhibition of PGDH may be used in combination with any prostaglandin or prostaglandin analogue which is suitable for inclusion in the present compositions by nature of its vasodilating activity.

The present suppositories may be manufactured by any standard method known to the art, including but not limited to extrusion, casting, and injection molding. For example, the present suppositories may be prepared by forming, under sterile conditions, an intimate mixture containing the appropriate relative amounts of components (a), (b), and (c) at temperature above the melting point of component (c) and then forming the suppository of the desired shape by extrusion, casting, or injection molding.

The present suppositories and methods offer a number of advantages as compared with conventional compositions and methods for treating male erectile dysfunction. In particular, the present suppositories and methods:

1. Eliminate the need for a device to administer the active agent;

2. Allows the use of a prostaglandin dosage that is remarkably smaller than the doses conventionally used with transurethral administration devices;

3. Permits manufacturing the composition with a greatly simplified process;

4. Results in a decreased exposure of the prostaglandin to light, heat, and moisture during manufacturing;

5. Results in reduced irritation to the urethra/meatus than conventional methods;

6. Allows the use of physiological concentrations of the naturally occurring prostaglandin and free fatty acids; and

7. Allows the treatment of patients with abnormal urethral anatomy; and

8. Allows the use of a meatal dose of prostaglandin that is remarkably smaller than previously demonstrated.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

I. PGDH Activity

A. Pig Penile Urethral Mucosa Preparation: Fresh hog penises from sexually mature animals are obtained from a local slaughter house. They are immediately washed in tap water and then in normal saline. The urethra corresponding to the section extending from the fossa navicularis and extending to the membraneous region of the urethra is separated from the corpus spongiosum. This region is called the penile urethra, and the corresponding length of the urethra is measured in millimeters and recorded. The weight of the urethra is also recorded. The mucosa is homogenized with four volumes of an ice-cold 100 mM potassium phosphate buffer (pH 7.5) containing 1 mM EDTA. Following centrifugation at 15,000 g for 15 minutes, the resultant supernatant fraction is used as the enzyme source of the penile mucosa.

B. 15-Hydroxyprostaglandindehydrogenase (PGDH) Activity Determination:

Spectrophotometric analysis:

As a substrate, prostaglandin E1 is incubated with the pig penile urethral mucosa prepared above. The reaction mixture is contained in a total volume of 2.0 ml of the same buffer used above for the preparation of the pig penile urethral mucosa preparation.

Prostaglandin E1 (50 microM) and NAD (300 microM) are used as substrates. The reaction is initiated by the addition of the prostaglandin E1. Incubation is done at 37° C. and is terminated by the addition of 0.5 mL of 2NaOH. The oxidation of the prostaglandin is assayed by monitoring the reduction of NAD+ at 340 nanometers in a spectrophotometer. Reaction times are adjusted so that the initial quantity of prostaglandin is oxidized by 50 to 80%.

Radiochemical determination: The same reactions conditions listed for spectrophotometric analysis are used except that (5, 6, 8, 11, 12, 14, 15(n)-3H)-prostaglandin E2 (specific activity, 171 Ci, mmol) from Dupont de Nemours is used as a typical substrate. Any other tritiated prostaglandin substrate can be utilized in this assay. To terminate the reaction, methanol precipitation (75% volume/volume)) is performed; then, water is added to dilute the methanol to 10 volume percent. Soluble phase extractions are performed using octadecyl 18-C silica cartridges (J. T. Baker, Deventer, Holland. Dried extracts are run on 20×20, 60A silica plates using the organic phase of ethyl acetate/acetic acid/isooctane/water (11:2:5:10:). Authentic prostaglandin E2. 15-keto-prostaglandin E2, and 13,14-dihydro-15-keto-prostaglandin E2 are comigrated on separate lanes. After localization of the compounds using phosphomolybdic spray, the silica is scraped, and the respective amounts of prostaglandin in E2 and. 15-keto-prostaglandin E2 are determined by radioactive counting. A mU is defined as that amount of enzyme which oxidizes 1 n mole of prostaglandin E2 or E1 per min at 37° C. pH 7.4. The number of mU PGDH per mm of pig penile urethra is then calculated by dividing the total number of mU by the mm of urethra used to prepare the enzyme.

II. PGDH Inhibitor Activity Determination.

In the context of the present invention, one pig penile unit of PGDH inhibition activity is defined as the quantity of inhibitor that prevents one percent of the quantity of prostaglandin present from being oxidized using the assay described below.

Spectrophotometric: Using the above listed spectrophotometric analytical system for PGDH activity, the inhibitor in question is added to the reaction mixture prior to the addition of the prostaglandin E1. At termination of the reaction, the quantity of the prostaglandin E1 degraded is calculated and compared to the reaction without the inhibitor. Percent inhibition is defined as B/A×100 where

A=nmoles of prostaglandin oxidized without inhibitor.

B=nmoles prostaglandin oxidized with inhibitor.

For example, if A=50 nmoles and B=25 nmoles with inhibitor C, then inhibitor C gives 25/50×100 or 50% inhibition in this assay.

Radiochemical Determination: The assay for inhibition is run with and without inhibitor added as listed above in the determination of PGDH activity radiochemically. A given inhibitor is added to the reaction mixture just prior to the addition of the prostaglandin E2 being analyzed and the analysis performed as listed. The quantity of prostaglandin oxidized is calculated and interpreted as listed above for spectrophotometric analysis of inhibitor activity.

Reference Example.

An aqueous solution containing 250 μg of PGE2, and 150 μg of phentolamine hydrochloride was applied directly to the urethra of a 42 year old male with a history of erectile dysfunction. An erection was produced in 10 minutes. It lasted for 60 minutes.

Example 1

1.500 Grams of ethyl stearate, 6.25 mg of PGE 2 and 62.5 mg of oleic acid were placed in a Pyrex test tube and heated to about 100° F. on a hot plate with periodic agitation. The mixture rapidly melted to afford a clear solution. A standard laboratory micropipette (Justor 1100BG manufactured by Nichiryo and available from Sigma, St. Louis, Mo. USA with volume dispensed adjustable from 10.0 to 100.0 microliters; and Sigma pipette tips—catalog #B-6429) was repeatedly dipped into this solution and aspirated with the volume set at 37 microliters. The solution rapidly solidified at ambient room temperature (71° F.) and the resultant suppository was removed by pressing a paper clip into the tip of the pipette. Approximately 100 suppositories were made in a two hour period using this method. Subsequent weighing showed that 96% of the suppositories weighed 31±0.5 mgs. Similar results were obtained when palmitic acid was substituted for oleic acid.

Example 2

Five men without any history of erectile dysfunction inserted a suppository composed of 125 μg of PGE 2, 1.25 mg of oleic acid in 30 mg of ethyl stearate, which measured 18 mm in length and about 2 mm in maximum diameter, prepared as described in Example 1, into their urethral meatus. The change in cavernosal arterial peak systolic blood flow was monitored before and after insertion with a Knoll/Midas® doppler ultrasound device. All five subjects experienced erectile responses that were sufficient for penetration. This length suppository delivers a meatal dose.

Example 3

A 46-year-old white male with multiple etiologies of erectile dysfunction including atherosclerosis, tobacco use, antidepressant use, and a 30-year history of phimosis and resulting obliteration of the glans penis by scarring was evaluated. Due to urethral strictures (from scar tissue), the urethra was narrowed to about 2 mm near the tip of the penis making insertion of a catheter impossible. A suppository (as described in Example 1) was easily and painlessly inserted into the urethra occluding it at the stricture. After 20 minutes, the patient experienced a firm erection, which lasted 60 minutes.

Example 4

Five men all with a history with erectile dysfunction inserted the same suppository described in Example 1 into their respective urethras. All five patients experienced erectile responses sufficient for penetration over the next 30 minutes.

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3070623Jun 26, 1958Dec 25, 1962Biorex Laboratories LtdPharmacological compounds
US3161654Jun 11, 1963Dec 15, 1964Merck & Co Incalpha-(1-aroyl-3-indolyl) alkanoic acids
US3647858May 1, 1970Mar 7, 1972Merck & Co IncProcess for preparing 1-benzylidene-3-indenyl acetic acids
US3654349May 1, 1970Apr 4, 1972Merck & Co IncSubstituted indenyl acetic acids
US3657327Jun 1, 1970Apr 18, 1972Upjohn CoProstaglandin salts of tris(hydroxymethyl)aminomethane
US3781429Sep 29, 1972Dec 25, 1973American Cyanamid CoMethod of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
US3800038Apr 21, 1972Mar 26, 1974Biolog Concepts IncUterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US3843681Jun 1, 1971Oct 22, 1974American Home Prod1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3911124Jan 28, 1974Oct 7, 1975Upjohn CoMethod of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3927213Jul 10, 1973Dec 16, 1975American Home ProdProstaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US3928588Feb 22, 1974Dec 23, 1975Upjohn CoMethod of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3948254Aug 28, 1974Apr 6, 1976Alza CorporationNovel drug delivery device
US3965143Mar 26, 1974Jun 22, 1976G. D. Searle & Co.Prostaglandin
US3967618Mar 6, 1975Jul 6, 1976Alza CorporationDrug delivery device
US3976660Aug 15, 1974Aug 24, 1976E. R. Squibb & Sons, Inc.Pyrrolidine derivatives
US4014987Jun 30, 1975Mar 29, 1977Alza CorporationDevice for delivery of useful agent
US4038415Sep 1, 1976Jul 26, 1977Nelson Research & Development CompanyEnzyme inhibitors
US4060691Dec 22, 1975Nov 29, 1977G. D. Searle & Co.7-{3-Hydroxy-2-[4-hydroxy-4-(lower alkyl)-trans-1-octen-1-yl]-5-oxocyclopent-1-yl}heptanoic acids and esters
US4085135Feb 11, 1977Apr 18, 1978Taisho Pharmaceutical Co., Ltd.Antiulcer
US4112942Jul 29, 1977Sep 12, 1978Reckitt & Colman Products LimitedMethod of preparing and administering a foam enema
US4127118Mar 16, 1977Nov 28, 1978Alvaro LatorreMethod of effecting and enhancing an erection
US4128577Dec 12, 1977Dec 5, 1978The Upjohn Company15-Methyl- and 16-phenoxy-PGF2 α, amides
US4178457Jul 10, 1978Dec 11, 1979Syntex (U.S.A.) Inc.(dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4198406Sep 21, 1977Apr 15, 1980Beecham Group LimitedAntibiotic
US4215128Sep 14, 1978Jul 29, 1980Beecham Group LimitedClavulanic acid derivatives their preparation and use
US4254145Aug 16, 1978Mar 3, 1981American Cyanamid CompanyLocalized vasocilation
US4271314Nov 28, 1979Jun 2, 1981G. D. Searle & Co.4,5-Unsaturated prostanoic acid derivatives
US4311707Feb 12, 1979Jan 19, 1982American Cyanamid CompanyProstaglandins
US4352790Jan 16, 1980Oct 5, 1982Perstorp AbMedical preparation containing prostaglandin
US4454339Jul 6, 1982Jun 12, 1984Schering Aktiengesellschaft9-Fluoroprostaglandin derivatives, and use as medicinal agents
US4503040Feb 27, 1984Mar 5, 1985Pfizer Inc.Treatment of bacterial infections
US4507323Jul 25, 1984Mar 26, 1985Burroughs Wellcome Co.Treatment of psychosexual dysfunctions
US4521421Sep 26, 1983Jun 4, 1985Eli Lilly And CompanyUsing 2-amino-octahydropyrimido(4,5-g)quinoline compound
US4539333May 10, 1977Sep 3, 1985Burroughs Wellcome Co.Prostacyclin, methods of using and method of making
US4564362Jul 7, 1983Jan 14, 1986Burnhill Michael SOpen-celled foam for use with medicines and contraceptives
US4680312Nov 21, 1984Jul 14, 1987The Upjohn CompanyStable prostaglandin E gels utilizing colloidal silicon dioxide as a gel-forming agent
US4683328Nov 25, 1985Jul 28, 1987G. D. Searle & Co.Tetraenyl prostaglandins
US4684633Jan 14, 1985Aug 4, 1987The Green Cross CorporationPhospholipid-emulsified prostaglandin composition
US4725439Jan 13, 1986Feb 16, 1988Alza CorporationReinforced matrix containing drug reservoir
US4766889Jun 26, 1986Aug 30, 1988Medical Engineering CorporationInfusion erectile system
US4801587Mar 2, 1987Jan 31, 1989Gene VossVasodilators
US4818517Jan 20, 1987Apr 4, 1989Akzo N.V.Drug, water-insoluble swellable polymer, water-soluble thickener
US4829991Jan 6, 1987May 16, 1989Medical Engineering Corp.Method and device for stimulating an erection
US4857059Apr 24, 1987Aug 15, 1989Centre National De La Recherche ScientifiqueRechargeable implantable device for dosed and repeated self-injection of medicament
US4867982Jan 26, 1988Sep 19, 1989Alza CorporationTransdermal drug delivery device
US4961931Sep 9, 1988Oct 9, 1990Alza CorporationMethod for the management of hyperplasia
US4976692Sep 25, 1989Dec 11, 1990Travenol Laboratories (Israel) Ltd.Catheter particularly useful for inducing labor and/or for the application of a pharmaceutical substance to the cervix of the uterus
US5015431Aug 29, 1989May 14, 1991The Kendall CompanyProcess for making model skin
US5049384Jul 7, 1989Sep 17, 1991Kim Young SPenicillins
US5059603Jun 12, 1989Oct 22, 1991Centuries Laboratories, Inc.Method and composition for treating impotence
US5145852Jul 10, 1990Sep 8, 1992Ronald ViragVaso-active medicament to treat impotence
US5147855Jul 7, 1989Sep 15, 1992Yeda Research And Development Co. Ltd.Modified vasoactive intestinal peptide
US5190967Jun 4, 1991Mar 2, 1993Glaxo Group LimitedMedicaments for treating erectile disorders
US5242391Oct 30, 1991Sep 7, 1993Alza CorporationUrethral insert for treatment of erectile dysfunction
US5256652Aug 27, 1990Oct 26, 1993Pharmedic Co.Topical compositions and methods for treatment of male impotence
US5270323Mar 11, 1993Dec 14, 1993Pfizer Inc.Method of treating impotence
US5474535Jul 19, 1993Dec 12, 1995Vivus, Inc.Dosage and inserter for treatment of erectile dysfunction
US5482039Mar 25, 1994Jan 9, 1996Vivus, Inc.Process for diagnosing erectile dysfunction, and related methods of treatment
US5565466Aug 9, 1994Oct 15, 1996Zonagen, Inc.Methods for modulating the human sexual response
US5571118Jan 5, 1995Nov 5, 1996Boutos; DavidApparatus for stimulating penile, scrotal, anal, vaginal and clitoral tissue
US5574068Nov 14, 1994Nov 12, 1996Brigham And Woman's HospitalS-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5576290Jun 24, 1994Nov 19, 1996Competitive Technologies, Inc.Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction
US5583144Feb 24, 1995Dec 10, 1996Kral; John G.Methods for treating erectile impotence
US5601343Aug 31, 1994Feb 11, 1997Hoffken; RudigerUnitary wheel system for road vehicles
US5612314Apr 21, 1995Mar 18, 1997Brigham & Women's HospitalNitrosylated neuropeptides
US5631284Oct 6, 1993May 20, 1997University Of British ColumbiaCompositions and methods for relaxing smooth muscles
US5646181May 2, 1995Jul 8, 1997Research Foundation Of State University Of New YorkMethod and compositions for treating impotence
US5648393Aug 29, 1994Jul 15, 1997Brigham & Women's HospitalTreatment of male impotence with s-nitrosylated compounds
US5681850Oct 31, 1995Oct 28, 1997Froelich; Juergen C.Method of treatment of impotence with prostaglandin E1 derivatives
US5698225Feb 3, 1997Dec 16, 1997G. D. Searle & Co.A core of nonsteroidal anti-inflammatory antiarthritic agent surrounded by coatings comprising misoprostol an anti-ulcer agent for side effect reduction; drug delivery
US5698589Jan 30, 1996Dec 16, 1997International Medical Innovations, Inc.Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5708031Jul 12, 1993Jan 13, 1998Scott; Nathan E.Prostaglandin E2 treatment of impotence
US5718917Dec 15, 1995Feb 17, 1998Harvard Scientific CorporationPGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
US5731339Apr 28, 1995Mar 24, 1998Zonagen, Inc.Administering vasodilator; phentolamine mesylate or hydrochloride
US5741523Sep 6, 1994Apr 21, 1998Pharmacia & Upjohn CompanyStabilized prostaglandin E1
US5769088Sep 27, 1995Jun 23, 1998Vivus, Inc.Process and kits for diagnosing erectile dysfunction, and related methods of treatment
US5770230Dec 30, 1996Jun 23, 1998Pharmacia & Upjohn CompanyMethod for preparing stabilized prostaglandin E1
US5770606Oct 20, 1995Jun 23, 1998Pentech Pharmaceuticals, Inc.Administering apomorphine
US5773020Oct 28, 1997Jun 30, 1998Vivus, Inc.Treatment of erectile dysfunction
US5820587Mar 17, 1997Oct 13, 1998Vivus IncorporatedMethod and kit for preventing erectile dysfunction
US5855548Jan 10, 1997Jan 5, 1999Vivus, IncorporatedVenous flow control element for maintaining penile erection
US5877216Oct 28, 1997Mar 2, 1999Vivus, IncorporatedTreatment of female sexual dysfunction
US5886039Jun 7, 1995Mar 23, 1999Kock; Nils G.Administering to uretha a lipophilic active agent selected from the group consisting of vasoactive prostaglandins
US5891915May 1, 1998Apr 6, 1999Wysor; Michael S.Method for enhancing female sexual response and an ointment therefor
US5905091Jul 1, 1997May 18, 1999The Board Of Regents Of The University Of OklahomaEnhancement of skin pigmentation by prostaglandins
US5919474Oct 28, 1997Jul 6, 1999Vivus, Inc.Using prostaglandins
US5922341Oct 28, 1997Jul 13, 1999Vivus, IncorporatedAdministering an antidepressant, antiserotonin agent or adrenergic blocking agent
US5925629Oct 28, 1997Jul 20, 1999Vivus, IncorporatedSexual dysfunction
EP0357581B1Aug 31, 1989Jul 28, 1993AMSU, Ltd.Composition for the treatment of erectile dysfunction
WO1994028902A1May 13, 1994Dec 22, 1994Peter EllisPyrazolopyrimidinones for the treatment of impotence
WO1996016644A1Oct 16, 1995Jun 6, 1996Simon Fraser CampbellcGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION
WO1999021558A2Oct 28, 1998May 6, 1999Vivus IncLocal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
Non-Patent Citations
Reference
1"Prostaglandin, Prosiacyclin and Thromboxant A2," 672-678.
2Akkus E. et al., "Duplex Ultrasonograpy After Prostaglandin E1 Injection of the Clitoris in a Case of Hyperreactio Luteinalis," vol. 153:1237-1238, Apr. 1995.
3Alam et al., Endocrinology, vol. 98(4):859-863, 1976.
4Althof et al., J. Sex & Marital Therapy, vol. 13:155-167, 1987.
5Anggard E. et al., Agents and Actions, vol. 6/4:498-504, 1976.
6Anggard et al., Ark. Kem., vol. 25:293-300, 1996.
7Baker, M.E., Steroids, vol. 59:136-141, 1994.
8Basar et al., International Urology and Nephrology, vol. 29: 667-671, 1997.
9Benkert et al., Psychopharmacologia, vol. 23:91-95, 1972.
10Bergstrom et al., Acta Chem, Scand., vol. 16:501-504, 1962.
11Bergstrom et al., J. Biol. Chem., vol. 238:3555-3564, 1963.
12Berry et al., Biochemical Pharmacology, vol. 32:2863-2871, 1983.
13Bodner et al., J. Urol., vol. 138:310-311, 1987.
14Cawello et al., Journal of Urology,vol. 158:1403-1407, 1997.
15Chang et al., Biochem. Biophys, Res. Commun., vol. 99:745-751, 1981.
16Chang, Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 19:225-228, 1989.
17Chen et al., Journal of Clinical Ultrasound, vol. 20:247-253, 1992.
18Corey et al., J. Am. Chem. Soc., vol. 92:397, 1970.
19Corey et al., J. Am.Chem. Soc., vol. 92:2586, 1970.
20Corey et al., J.Am. Chem. Soc., vol. 91:535, 1969.
21Diagnostic and Statistical Manual IV, "Sexual and Gender Identity Disorder", American Psychiatric Association, Washington, D.C., 493-539 ad 735,751, 1994.
22Ensor et al., J. Lipid Mediators Cell Signalling, vol. 12:313-319, 1995.
23Etodolac, 559.
24Etofenamate, 559.
25Foldvari et al., European Journal of Drug Metabolism and Pharmacokinetics, vol. 22(2):111-120, 1997.
26Franchi et al., Prostaglandins, vol. 29(6):953-960, 1985.
27Frank et al., New England Journal of Medicine, vol. 299:111-115, 1978.
28Futterweit et al., Metabolism, vol. 33(10):936-942, 1984.
29Galea, G. et al., J. Urology, vol. 159:236, Abstract No. 903, 1998.
30Garde et al., Maturitas, vol. 2:225-240, 1980.
31Goldstein et al., Abstract #919, The Journal of Urology, vol. 159(5):240, May 1998.
32Goldstein et al., N. England J. Med., vol. 338:1397-1404, 1998.
33Goodman & Gilman et al., "The Pharmacological Basis of Therapeutics" (6th Edition), New York, 668-678,1980.
34Gringanz, Introduction to Medicinal Chemistry, Wiley-VCH, Inc., New York, 155-161 and 640-643, 1997.
35Handelsman, "Diagnosis and Treatment of Impotence" in AHCPR Health Technology Assessment Reports, No. 2, pp. 1-24, 1990.
36Harrison's Principles of Internal Medicine, Thirteenth Ed., K.J. Isselbacher et al., Eds., McGraw-Hill, Inc., New York, 2492, 1994.
37Heather et al., Tetrahedron Letters, 2313-2316, 1973.
38Hedlund H. et al., J. Urol., vol. 134:1245-1250, 1985.
39Herin Padam-Nathan et al., New England Journal of Medicine, vol. 336:1-7, Jan. 2, 1997.
40Hosoda et al., J. Og. Chem., vol. 38:4209,1973.
41Hyyppa et al. in Sexual Behavior Pharmacology and Biochemistry, M. Sandler et al., Plenum Press, New York, 315-327, 1975.
42Iijima, Y. et al., Biochem., and Biophys., Res. Commun., vol. 80484-489, 1978.
43Introduction to Medicinal Chemistry, "Representative Prostaglandin Compounds in Use," 158-159 and 641-642.
44Ishii, N. et al., J. of Urol., vol. 141:323-325, 1989.
45Jarabak et al., Prostaglandins, vol. 18:241-246, 1979.
46Jarabak, J., Prostaglandins, vol. 35:403-411, 1988.
47Krane, Robert J. et al., N. Eng. J. Med., vol. 321(24): 1648-1659,1989.
48Kung-Chao, D.T.Y. et al., Biochemica et Biophysica Acta, vol. 614:1-13, 1980.
49Lal et al., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., vol. 11:235-242, 1987.
50Levin, R.J., "The Physiology of Sexual Function in Women," vol. 7(2):213-253, Aug. 1980.
51Lin et al., Biochem., Biophys, Res. Commun., vol. 81:1227-1234, 1978.
52Linet et al., New England Journal of Medicine, vol. 334:873-877, Apr. 4, 1996.
53Lopiccolo, J. et al., J. of Counseling and Clinical Psychology, vol. 54(2): 158-167, 1986.
54MacDonald, Biochem, Biophys, Acta., vol. 1061:297-303, 1991.
55MacDonald, R.C. et al., "Small-Volume Extrusion Apparatus for Preparation of Large, Unilamellar Vesicles," 297-303, Jul. 23, 1990.
56Mak et al., Biochimica et Biophysica Acta, 1035:190-196, 1990.
57Merck Index, 10th Edition, citation 4368, 1983.
58Mibe, M. et al., Prostaglandins Leukotrienes and Essential FattyAcids, vol. 46:241-254, 1992.
59Migeon et al., The Johns Hopkins Medial Journal, vol. 123:128-133, 1968.
60Moncada, S. et al., "Prostaglandins, Prostacyclin, and Thromboxane A2," 668-678.
61Muramatsu, M. Biochemical Pharmacology, vol. 33:2629-2633, 1984.
62Nathan, J. of Sex and MaritalTherapy, vol. 12(4):267-281, 1986.
63Notification of Transmittal of hte International Search Report of the Declration issued on Nov. 17, 1998, In corresponding PCT/US98/13439.
64Osborn et al., British Medical Journal, vol. 296:959-962, 1988.
65Peskar et al., J. Pharm. Pharmacol., vol. 28:146-148, 1976.
66Pichaud, F. et al., Blood, vol. 89:2105-2112, 1997.
67Porst, H., J. Urology, vol. 155:802-815, 1996.
68Proceeding of the American Urological Association, vol. 153, Apr. 1995 Supplement, Abstracts 976 and 977.
69Rosen et al., Archives of Sexual Behavior, vol. 22(6):521-543, 1993.
70Roy, A.C., et al., Brit. J. Urology, vol. 64:180-182, 1989.
71Sakuma, S. et al., Prostaglandins, vol. 40:507-514, 1990.
72Sarrel, P.M., "Sexuality and Menopause," 26S-30S, Sep. 29, 1989.
73Schaaf et al., J. Org. Chem., vol. 37:2921, 1974.
74Schmidt, JAMA, vol. 259(21):3176, 1988.
75Siegel-Itzkovich, BMJ, vol. 316:1625, 1998.
76Sih et al., J. Am. Chem. Soc., vol. 94:3643, 1972.
77Sih et al., J. Am. Chem. Soc., vol. 95:1676, 1973.
78Slates et al., Tetrahedron, vol. 30:819-830, 1974.
79Stackl et al., Journal of Urology, vol. 140:66-68, 1998.
80Stief, C.G. et al., J. Urology, vol. 159:1390-1393, 1998.
81Tai, C.L. et al., Biochem., J., vol. 267:75-78, 1990.
82Takeuchi, K. et al., Gen. Pharmac., vol. 30:739-744, 1988.
83Uekama et al., J. Pharm. Sci., vol. 73:382-384, 1984.
84Utiger, N. England J. Med., vol. 338:1458-1459, 1998.
85Van Ahlen et al., Journal of Urology, vol. 151:1227-1230, 1994.
86Virag et al., Angiol., vol. 35:79-87, 1984.
87Virag et al., Angiology, vol. 35:79-87, 1984.
88Virag et al., J. of Urol., vol. 137:1010, 1987.
89Virag et al., J. Urology, vol. 137:1010, 1987.
90Waldhauser, M. et al., J. Urology, vol. 140:525-527, 1988.
91Willimann, H. et al., J. Pharmaceutical Sciences, vol. 81:871-874, 1992.
92Wolfson et al., Urology, vol. 42:73-75, 1993.
93Written Opinion issued on Jul. 12, 1999, In corresponding PCT Application No. PCT/US98/13439.
94Yamamura et al., J. Chromatogr., vol. 303:165-172, 1984.
95Yamamura et al., J. Chromatogr., vol. 331:383-388, 1985.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7846400Jan 11, 2008Dec 7, 2010The Invention Science Fund I, Llccomprising light sources, rare-earth materials configured for upconversion of light, photolyzable nitric oxide donors, sensors configured to detect nitric oxide, and controllers
US7862598Dec 21, 2007Jan 4, 2011The Invention Science Fund I, LlcDevices and systems that deliver nitric oxide
US7897399Dec 21, 2007Mar 1, 2011The Invention Science Fund I, LlcNitric oxide sensors and systems
US7975699Dec 21, 2007Jul 12, 2011The Invention Science Fund I, LlcCondoms configured to facilitate release of nitric oxide
US8221690Nov 30, 2007Jul 17, 2012The Invention Science Fund I, LlcSystems and devices that utilize photolyzable nitric oxide donors
US8349262Jan 11, 2008Jan 8, 2013The Invention Science Fund I, LlcNitric oxide permeable housings
US8642093Oct 30, 2007Feb 4, 2014The Invention Science Fund I, LlcMethods and systems for use of photolyzable nitric oxide donors
Classifications
U.S. Classification514/573, 514/33, 514/691, 514/574
International ClassificationA61K31/12, A61K36/48, A61K31/201, A61K31/198, A61K31/19, A61K31/20, A61K45/00, A61K31/5575, A61K31/192, A61K9/06, A61K9/08, A61K31/122, A61K9/02, A61P15/10, A61K31/194, A61K31/215, A61K31/557, A61K9/00, A61K45/06, A61K31/70
Cooperative ClassificationA61K9/02, A61K9/0034, A61K45/06, A61K31/557, A61K31/70
European ClassificationA61K31/557, A61K31/70, A61K9/02, A61K45/06, A61K9/00M8
Legal Events
DateCodeEventDescription
Nov 8, 2010FPAYFee payment
Year of fee payment: 8
May 7, 2007SULPSurcharge for late payment
May 7, 2007FPAYFee payment
Year of fee payment: 4
Nov 22, 2006REMIMaintenance fee reminder mailed